论文部分内容阅读
目的观察三维适形放疗(3D-CRT)、同步化疗加羟基喜树碱热灌注化疗治疗晚期膀胱癌的临床疗效及不良反应。方法将37例晚期膀胱癌患者随机分为两组,均采用3D-CRT加GC方案(吉西他滨+顺铂)化疗,观察组加用羟基喜树碱热灌注化疗。放射治疗结束1个月后,比较两组近期疗效及不良反应;随访2 a,评价远期疗效和生存率。结果观察组有效率高于对照组(P<0.05)。观察组白细胞下降、血小板减少、恶心呕吐、肝功能异常等不良反应发生率稍高于对照组,但无统计学差异(P>0.05)。两组2 a生存率比较无统计学差异(P>0.05)。结论 3D-CRT、同步化疗加羟基喜树碱热灌注化疗治疗晚期膀胱癌疗效较好,可明显提高近期疗效,不良反应稍有增加,但患者能耐受,未能提高患者的生存率。
Objective To observe the clinical efficacy and side effects of three-dimensional conformal radiotherapy (3D-CRT) and concurrent chemotherapeutic hydroxycamptothecin (HCPT) chemotherapy in the treatment of advanced bladder cancer. Methods Thirty-seven patients with advanced bladder cancer were randomly divided into two groups. All patients were treated with 3D-CRT plus GC (gemcitabine plus cisplatin) chemotherapy. Hydroxycamptothecine was used in the observation group. One month after the end of radiotherapy, the short-term efficacy and adverse reactions were compared between two groups. The follow-up was performed for 2 years to evaluate the long-term efficacy and survival rate. Results The observation group was more effective than the control group (P <0.05). The incidence of adverse reactions such as leukopenia, thrombocytopenia, nausea and vomiting, abnormal liver function in the observation group was slightly higher than that in the control group, but there was no significant difference (P> 0.05). There was no significant difference in the 2-year survival rate between the two groups (P> 0.05). Conclusions 3D-CRT, simultaneous chemotherapeutic plus hydroxycamptothecin, hyperthermic chemotherapy is better for advanced bladder cancer and can significantly improve the short-term curative effect with a slight increase in adverse reactions. However, patients can tolerate these drugs and fail to improve the survival rate of patients with advanced bladder cancer.